[ad_1]
Johnson & Johnson’s coronavirus vaccine was 72 percent effective in the first data from a late-stage U.S. trial, the company said Friday. But the vaccine’s efficacy fell to 52 percent against a virus variant first identified in South Africa.
The highly anticipated vaccine has several logistical advantages over authorized shots from Moderna and Pfizer: It is given as one dose and can be stored in refrigerators, rather than freezers.
The United States has purchased 100 million doses of the Johnson & Johnson vaccine with an option to buy an additional 200 million doses.
[ad_2]
Source link
